DPO-1 | 207220-71-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: DPO-1
• 英文别名: (2-isopropyl-5-methylcyclohexyl)(diphenyl)phosphine oxide；(2-isopropyl-5-methylcyclohexyl)diphenyl-phosphine oxide；(2-Isopropyl-5-methylcyclohexyl)diphenylphosphine oxide；neomenthyldiphenyl phosphine oxide；Phosphine oxide, [5-methyl-2-(1-methylethyl)cyclohexyl]diphenyl-；[(5-methyl-2-propan-2-ylcyclohexyl)-phenylphosphoryl]benzene
• CAS: 207220-71-1
• 化学式: C₂₂H₂₉OP
• 分子量: 340.445
• InChiKey: BPCNGVCAHAIZEE-UHFFFAOYSA-N

物化性质

• 沸点：
  435.0±14.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  BrCl2 、 neomenthyldiphenylphosphine 生成 DPO-1
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY<br/>[FR] DÉRIVÉS D'HÉTÉROARYLSULFONAMIDES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPIE HUMAINE
  申请人：PF MEDICAMENT

  公开号：WO2012069503A1

  公开（公告）日：2012-05-31

  The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C1-C4 alkyl, or linear or branched C1-C4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents −C(=O)-, or B represents CH when n=0 and D represents −CH2O− or when n=1 and D represents −O−, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

  本发明涉及杂环磺酰胺衍生物，特别是作为Kv钾通道的阻滞剂，更具体地是Kv1.5、Kv4.3或Kv11.1通道的阻滞剂，它们在临床治疗中的应用以及它们的制备方法。这些化合物对应于以下一般式（I）：其中R1代表苯环X的一个或多个取代基，如：氢、卤素、三氟甲基、三氟甲氧基、直链或支链C1-C4烷基，或直链或支链C1-C4烷氧基，A代表氧或硫，当n=1或2时，B代表氮，D代表−C(=O)-；当n=0时，B代表CH，D代表−CH2O−；当n=1时，B代表CH，D代表−O−，R2代表氢、甲基、氟或氯原子或甲氧基，HetAr代表可能被直链或支链C1-C4烷基、直链或支链C1-C4烷氧基、卤素或三氟甲基等取代的吡啶基或喹啉基，以及它们的药用可接受盐。
• DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY
  申请人：Dupont-Passelaigue Elisabeth

  公开号：US20130172326A1

  公开（公告）日：2013-07-04

  The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C 1 -C 4 alkyl, or linear or branched C 1 -C 4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents —C(═O)—, or B represents CH when n=0 and D represents —CH 2 O— or when n=1 and D represents —O—, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C 1 -C 4 alkyl, a linear or branched C 1 -C 4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

  本发明涉及杂环磺胺类衍生物，特别是作为Kv钾通道的阻滞剂，更具体地是Kv1.5、Kv4.3或Kv11.1通道的阻滞剂，它们在临床治疗中的应用以及它们的制备方法。这些化合物对应于以下一般式（I）：其中R1代表苯环X的一个或多个取代基，如：氢、卤素、三氟甲基、三氟甲氧基、直链或支链的C1-C4烷基，或直链或支链的C1-C4烷氧基，A代表氧或硫，当n=1或2时，B代表氮，D代表—C(═O)—，或当n=0时，B代表CH，D代表—CH2O—或当n=1时，D代表—O—，R2代表氢、甲基、氟或氯原子或甲氧基，HetAr代表可能被直链或支链的C1-C4烷基、直链或支链的C1-C4烷氧基、卤素或三氟甲基等取代的吡啶基或喹啉基，以及它们的药学上可接受的盐。
• DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS
  申请人：Dupont-Passelaigue Elisabeth

  公开号：US20130267520A1

  公开（公告）日：2013-10-10

  The present invention relates to diarylpyridazinone derivatives that block the potassium Kv channels (specifically the Kv1.5, Kv4.3, and Kv11.1 channels) and to the use thereof for the treatment of humans. Said compounds have the general formula (I), where R 1 and R 2 are simultaneously or independently one or more groupings such as: halogen, such as F, Br, Cl, a straight or branched C 1 -C 4 alkyl, hydroxy, a straight or branched C 1 -C 4 alkoxy, arylsulfonamido, in which the aryl is optionally replaced with a straight or branched C 1 -C 4 alkyl, or nitrile, as well as the various enantiomers and the mixtures thereof in any proportion, and the pharmaceutically acceptable salts thereof.

  本发明涉及一种阻断钾Kv通道（具体是Kv1.5、Kv4.3和Kv11.1通道）的二芳基吡啉二酮衍生物，以及其用于治疗人类的用途。所述化合物具有通式（I），其中R1和R2同时或独立地是卤素，如F、Br、Cl，直链或支链的C1-C4烷基，羟基，直链或支链的C1-C4烷氧基，芳基磺酰胺基，其中芳基可选地被直链或支链的C1-C4烷基取代，或腈，以及各种对映体和它们的任何比例的混合物，以及其药学上可接受的盐。
• Use of Flavone Compounds as Potassium Channel Inhibitors
  申请人：Li Gui-Rong

  公开号：US20080214493A1

  公开（公告）日：2008-09-04

  This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) using the leading flavone compound acacetin, and its derivatives and analogues that inhibit the ultra-rapidly-activating delayed rectifier potassium current (I Kur or I Ksus ), transient outward potassium (I to ), and acetylcholine-activated potassium current (I K.ACh ).

  本发明提供了一种使用领先的黄酮类化合物乙草胡桃素及其衍生物和类似物治疗或预防人类心房心律失常（颤动）的方法，该方法通过抑制超快速激活延迟整流钾电流（IKur或IKsus）、瞬时外向钾电流（Ito）和乙酰胆碱激活钾电流（IK.ACh）。
• METHODS OF TREATING OR PREVENTING CARDIAC ARRHYTHMIA
  申请人：Merck & Co., Inc.

  公开号：EP0948335B1

  公开（公告）日：2007-05-23